ArticleVeterinary research communications2026
Antioxidant protection by vanillin aldehyde against chronic pymetrozine-induced hepatic, renal, and DNA damage in African catfish.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Worldwide, aquatic ecosystems are increasingly threatened by the inappropriate overuse of insecticides, posing risks to aquatic life. There is a need for alternatives that are safe, economical, and environmentally friendly. Thus, the protective effects of dietary vanillin (VAN) against the detrimental consequences of long-term pymetrozine (PMZ) exposure in Clarias gariepinus (African catfish) are investigated in this study. To address this, fish were randomly assigned into four groups: control, VAN (10 mg/kg diet), PMZ (0.065 mg/L), and VAN + PMZ for two months, with 40 fish in each group. Chronic PMZ exposure significantly elevated the concentrations of alanine aminotransferase, aspartate aminotransferase, creatinine, glucose, cortisol, malondialdehyde, and 8-hydroxy-2’-deoxyguanosine by 131.44, 134.55, 564.28, 49.65, 76.00, 174.69, and 281.97%, respectively (P < 0.001), compared with the control. Conversely, total protein, albumin, globulin, total antioxidant capacity, and catalase activity decreased by 27.76, 32.73, 21.74, 58.20, and 60.41%, respectively (P < 0.001). Histological examination revealed that PMZ provoked a range of histopathological changes in the vital organs (liver, kidney, gills, and brain), including vacuolation, hydropic degeneration, and necrosis. Remarkably, VAN supplementation in the PMZ-exposed group significantly ameliorated these effects, reducing alanine aminotransferase (40.80%), aspartate aminotransferase (33.04%), creatinine (35.48%), glucose (22.70%), cortisol (18.39%), malondialdehyde (39.62%), and 8-hydroxy-2’-deoxyguanosine (26.18%) (P < 0.001). Moreover, it increased total protein, albumin, globulin, total antioxidant capacity, and catalase activity by 25.85, 34.67, 16.67, 404.08, and 364.86%, respectively (P < 0.001). Histological analyses of the VAN + PMZ group showed largely normal tissue architecture, with only mild hepatic cell degeneration, a few necrotic renal tubules, slight gill filament erosion, and occasional degenerated neurons. Dietary VAN also significantly reduced mortality from 37.50% (95% confidence interval: 24.20–53.00%) in the PMZ group to 12.50% (95% confidence interval: 5.50–26.10%) in the VAN + PMZ group (P = 0.018, Fisher’s exact test). In conclusion, dietary VAN demonstrates considerable potential in mitigating the adverse effects of PMZ on C. gariepinus. However, further field-based studies are warranted before recommending its application in aquaculture practice.
Indexed as
Identifiers
41569434What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.